In the past two decades, several third‐generation agents (osimertinib, aumolertinib, and furmonertinib) have been developed and revolutionized the therapeutic strategy for NSCLC patients with EGFR mutations [30]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.